7 best no-code EDC software platforms for CROs in 2026

A CRO running ten concurrent studies doesn't have the luxury of waiting 12 weeks for vendor programmers to configure a database. Every amendment cycle that stretches into months compounds across your portfolio, delaying billing milestones and straining sponsor relationships. Viedoc's EDC software delivers study builds in as few as 8 weeks with a no-code Designer that your data management team configures independently, supported by 24/7 customer success across 7,000-plus completed studies in 75-plus countries. This comparison evaluates seven leading no-code EDC platforms for CROs across build speed, self-service configuration capability, compliance credentials, and total cost of ownership.

CROs are evaluating platforms where in-house data managers can build and amend studies without vendor-side programmers. The industry benchmark for legacy enterprise platforms is 90 days per study build — a timeline that doesn't scale when you're managing a portfolio. No-code configuration eliminates programmer dependency, accelerates go-live dates, and gives your team direct control over study logic, edit checks, and amendment deployment.

Enterprise platforms built for big pharma Phase III programs deliver comprehensive compliance depth, but at a deployment cost and complexity that doesn't translate to SMID CROs running Phase I and Phase II studies at pace. What this segment needs is right-sized: fast to deploy, self-service by design, compliant without heavyweight validation overhead, and supported without a ticket queue.

Best no-code EDC software for CROs: quick comparison

1. Viedoc

Viedoc's EDC software is built for CROs that need to configure studies in-house without vendor programmer dependency. Study builds are typically completed in as few as 8 weeks using Viedoc Designer, a no-code interface that allows certified data managers to configure forms, edit checks, workflows, and randomization logic without writing code. CROs running multiple concurrent studies benefit from template reuse, consistent validation rules across portfolios, and direct control over amendment deployment — no scheduling delays waiting for vendor resources.

Viedoc's transparent pricing model eliminates per-user fees with unlimited user seats included in standard licensing, reducing overhead for CROs scaling teams across studies. The platform's modular structure lets you deploy EDC as a standalone solution or integrate Viedoc's ePRO, RTSM, eTMF, and Televisit modules as study requirements expand. Viedoc's CRO Partner Program provides tiered partnership levels with certified CRO designations, priority support escalation paths, and dedicated account management for preferred-vendor CRO relationships.

Viedoc is ISO 27001, ISO 9001, and SOC 2 Type II certified, with compliance coverage across FDA 21 CFR Part 11, ICH-GCP, EMA, EU Annex 11, GDPR, and HIPAA attestation for US PHI-handling studies. The Viedoc Inspection Readiness Packet (VIRP) provides structured computer system validation documentation at no additional cost, supporting audit readiness without heavyweight QA overhead. 24/7 customer success support is delivered directly from Viedoc's global offices — not routed through a ticket-only helpdesk — with real escalation paths for database lock, site activation, and amendment deployment milestones.

"Viedoc makes building a study easy and fun. It doesn't require extensive coding knowledge; it's quick to get in and start working." Cindy H., Project Support Associate

Verified proof points:

• Study scale: 7,000-plus completed studies across 75-plus countries
• User base: 140,000-plus users globally; 30,000-plus sites
• Build speed: Study builds typically completed in as few as 8 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• No-code designer: Viedoc Designer allows certified data managers to configure studies without vendor programmers
• Compliance: ISO 27001, ISO 9001, SOC 2 Type II certified; FDA 21 CFR Part 11, ICH-GCP, EMA, EU Annex 11, GDPR, HIPAA attestation
• Support: 24/7 customer success support across global offices
• Training: Certified Designer training program; average two days to proficiency

2. Medidata

Medidata offers Rave EDC, the most widely deployed electronic data capture platform globally, supporting 30,000-plus clinical trials across pharmaceutical, biotech, and CRO organizations. Rave EDC provides comprehensive clinical data management capabilities including electronic case report form design, real-time validation, medical coding integration, imaging data capture, and targeted source data verification. The platform is part of the broader Medidata ecosystem, with deep integration across CTMS, eTMF, RTSM, and patient engagement tools within a unified clinical cloud architecture. Medidata's Designer Central provides a centralized study build hub, though traditional Rave configurations have historically required specialized Rave programmers for form logic and edit check development. Medidata is the default choice for large pharmaceutical Phase III programs and serves as the category benchmark for enterprise EDC deployment.

3. Veeva

Veeva offers Vault EDC, a cloud-based electronic data capture platform within the broader Veeva Vault ecosystem. Vault EDC features a visual drag-and-drop study designer that enables study builders to configure case report forms and quality control checks without custom programming. The platform supports zero-downtime protocol amendments, allowing study design changes to be deployed to active trials without taking the system offline or migrating data. Veeva reports that pharmaceutical company GSK achieved a 50% reduction in study build times using Vault EDC, with median study build times across the customer base of 7.4 weeks. Vault EDC integrates tightly with Veeva's CTMS, eTMF, and regulatory information management tools, providing strong value for sponsors already embedded in the Veeva ecosystem. The platform is designed for end-to-end clinical data management from study start through database lock and archiving.

4. Castor EDC

Castor EDC provides a no-code, self-service electronic data capture platform designed for rapid study deployment. The platform features drag-and-drop eCRF creation, with 90% of Castor studies passing user acceptance testing in under four weeks according to the company. Castor's API-first architecture enables seamless integration with EMR/EHR systems via HL7 FHIR, along with ePRO, eCOA, and device data sources into a centralized clinical data platform. The platform supports automated randomization, real-time monitoring, and data export in CSV, Excel, SPSS, and CDISC formats. Castor maintains ISO 27001, ISO 9001, HIPAA, GCP, 21 CFR Part 11, and GDPR compliance, with audit trails and granular user management built into the platform. Castor has been used across 15,000 studies with 8 million participants in 90 countries, with strong traction in academic research, early-phase commercial trials, and medical device studies.

5. Medrio

Medrio delivers a cloud-based electronic data capture and clinical data management system with point-and-click configuration that enables study teams to build databases without programming expertise. Medrio customers complete study builds in under three weeks on average according to the company, compared to industry averages of 12 weeks, with mid-study amendments implemented in as little as one day with no system downtime. The platform provides a modular eClinical suite including EDC, eCOA/ePRO, eConsent, and RTSM capabilities that can be activated independently or as an integrated environment. Medrio supports both online and offline data capture, relevant for sites with unreliable connectivity, and is validated for FDA 21 CFR Part 11, ICH-GCP, HIPAA, and GDPR compliance. The platform is designed for pharmaceutical, biotech, medical device, CRO, and animal health organizations across all trial phases, with particular strength in Phase I and medical device studies where rapid deployment and flexible amendment workflows are priorities.

6. Oracle Health

Oracle Health offers InForm EDC, a legacy enterprise electronic data capture system historically deployed across global multi-site Phase III clinical trials. InForm has deep penetration in large pharmaceutical organizations and provides comprehensive integration across Oracle Health Sciences suite including safety, CTMS, and randomization tools. The platform supports complex protocol designs and global regulatory requirements with validated integration libraries built over decades of deployment. Oracle's corporate scale provides procurement comfort for large enterprises prioritizing vendor stability and long-term support commitments. InForm is widely regarded as legacy technology with a dated user interface compared to modern cloud-native platforms, and mid-study amendment workflows are slower than contemporary no-code competitors. The platform is architected for complexity at scale rather than rapid deployment for SMID CRO portfolios.

7. Merative

Merative offers Zelta CDMS, a cloud-based electronic data capture platform with drag-and-drop form builder and real-time data review capabilities. Zelta emphasizes study design flexibility and mid-study amendment management, with protocol amendment workflows designed to handle frequent study design changes without system downtime. The platform provides centralized access via single sign-on, supporting researchers across all trial phases, therapeutic areas, and complexity levels. Zelta integrates AI-assisted study design capabilities with electronic data capture functionality, aimed at simplifying clinical research execution. The platform originated from IBM's healthcare technology division and has undergone rebranding and repositioning in recent years, with uncertain long-term product direction compared to more established EDC vendors.

What to look for in no-code EDC software for CROs

Study build and amendment velocity

Build timelines directly impact CRO delivery margins and sponsor milestone dates. A 90-day build cycle — still standard for legacy enterprise platforms — isn't a minor inconvenience when you're running ten concurrent studies. It's months of delayed billing, strained sponsor relationships, and compounded delivery risk across your entire portfolio. Amendment speed matters just as much: a protocol change that takes 60 days to implement multiplies across every active study in your pipeline.

Best-in-class no-code platforms deliver study builds in 3 to 8 weeks, with amendment turnaround measured in days rather than quarters. Viedoc's EDC software typically completes builds in as few as 8 weeks. Platforms that require vendor-side programmers for every logic change create scheduling dependencies that compound across a portfolio — no-code configuration eliminates this bottleneck entirely.

CROs running multiple concurrent studies can't absorb 90-day build cycles without sacrificing sponsor competitiveness or margin pressure. Every week of build delay is a week of delayed go-live, delayed data collection, and delayed invoicing.

Self-service configuration capability

Data management teams need to build and amend studies without deep vendor dependency. Every build that requires vendor programming adds cost and creates a scheduling dependency that compounds across a portfolio. True no-code platforms allow certified data managers to configure forms, edit checks, randomization logic, and workflows independently — no programmer required.

Platforms with genuine no-code designers let your team deploy studies in-house, iterate on CRF logic during UAT, and push amendments directly without vendor scheduling bottlenecks. Viedoc Designer, Castor's drag-and-drop builder, and Medrio's point-and-click interface are examples of genuine self-service capability. Platforms that market themselves as "low-code" often still require vendor specialists for complex edit checks or randomization configurations — verify actual self-service scope during technical evaluation.

CROs that can't self-build are locked into vendor timelines for every study launch and every amendment. This creates margin pressure, delivery risk, and sponsor frustration when amendment cycles stretch into months.

Compliance and validation readiness

GCP, FDA, EMA, EU Annex 11, and GDPR compliance are requirements, not differentiators. QA and CSV gatekeepers will disqualify non-compliant platforms at the RFP stage. ISO 27001 and SOC 2 certifications signal mature security programs; HIPAA attestation is required for US PHI-handling studies. Platforms without these baseline credentials won't pass sponsor procurement review.

Validation documentation matters as much as the certifications themselves. Viedoc's Inspection Readiness Packet (VIRP) provides structured computer system validation materials at no additional cost — critical for CROs supporting sponsor audits without heavyweight QA overhead. Platforms that charge separately for validation packs or require extensive validation effort inflate total cost of ownership.

Compliance gaps discovered during sponsor QA review can kill deals late in the sales cycle. Verify baseline certifications and validation pack availability before shortlisting platforms.

Support model and escalation infrastructure

24/7 support is non-negotiable for studies running across time zones. Response SLAs matter most at database lock, site activation, and amendment deployment — moments when ticket-only support creates unacceptable risk. Platforms that route all inquiries through helpdesk ticketing without real escalation paths leave CROs exposed when sponsors need answers in hours, not days.

Best-in-class support includes named account management, direct escalation to technical experts, and support delivered from the vendor's own offices rather than outsourced call centers. Viedoc's 24/7 customer success is staffed from global Viedoc offices with direct escalation pathways — not routed through a ticket queue. Medidata and Veeva offer tiered support with account management for enterprise customers; smaller platforms may offer responsive support but with limited global coverage.

Ticket-only support fails at the moments that matter most: database lock weekends, urgent sponsor queries, and amendment deployment deadlines. Verify actual escalation infrastructure and named account management availability during vendor evaluation.

Pricing transparency and cost predictability

Per-user licensing models penalize CROs for headcount growth. Platforms that charge per seat create margin pressure as study teams scale — exactly the wrong incentive structure for a growing CRO. Study-based licensing with unlimited user seats eliminates this friction and provides cost predictability across portfolio expansion.

Hidden fees for validation packs, amendment support, or "professional services" that should be standard inflate total cost of ownership. Viedoc's transparent, modular pricing includes unlimited user seats with no hidden setup fees for self-build clients. Medidata and Veeva negotiate enterprise contracts with complex pricing tiers; Castor and Medrio offer more straightforward per-study models. Verify actual all-in costs including amendments, user additions, and validation support before finalizing vendor selection.

CROs evaluating platforms should model total cost of ownership across a three-year portfolio, not just per-study list pricing. Amendment fees, user seat overages, and validation pack charges can double effective costs.

How to choose the right no-code EDC platform for CROs

Step 1: Define portfolio scope and study complexity

Match platform capability to your actual trial mix. If you're running Phase I and Phase II studies for SMID biotech sponsors, enterprise platforms architected for Phase III complexity are over-engineered and overpriced for your needs. Lightweight platforms designed for academic research may lack the validation depth and audit-readiness infrastructure sponsors expect. Define your typical study size (participant count, site count), phase distribution, and therapeutic area spread before evaluating vendors.

Step 2: Assess self-service build capability

Request a live demonstration of the study build interface with your own protocol as the test case. Verify that your data management team can configure forms, edit checks, and randomization logic without vendor programmer dependency. Ask vendors to walk through amendment deployment end-to-end — how long does a protocol change take from approval to live deployment? Platforms that require vendor support for routine amendments create scheduling bottlenecks that compound across portfolios.

Step 3: Evaluate compliance credentials and validation overhead

Confirm baseline certifications: ISO 27001, SOC 2, FDA 21 CFR Part 11, ICH-GCP, GDPR, and HIPAA attestation where relevant. Request validation documentation and inspection readiness materials during technical evaluation — platforms that charge separately for validation packs inflate total cost of ownership. QA and CSV stakeholders should review vendor-supplied validation materials before shortlisting vendors.

Step 4: Model total cost of ownership across three years

Calculate all-in costs including per-study licensing, user seats, amendment fees, validation packs, and support tiers. Per-user models penalize headcount growth; study-based licensing with unlimited seats provides better cost predictability for scaling CROs. Request pricing for a realistic three-year portfolio scenario — 15 to 30 concurrent studies across Phase I and Phase II — and compare effective per-study costs including all ancillary fees.

Step 5: Verify support infrastructure and account management

Confirm 24/7 support availability, escalation pathways, and named account management. Request references from CROs of similar size and study complexity, and ask specifically about support responsiveness at critical milestones: database lock weekends, urgent sponsor queries, and amendment deployment. Ticket-only support without real escalation infrastructure creates unacceptable risk for CROs managing sponsor relationships.

For CROs running Phase I and Phase II portfolios where speed and self-service capability drive competitive differentiation, Viedoc's EDC software delivers no-code study builds in as few as 8 weeks with unlimited user seats, 24/7 support, and transparent pricing. Book a demo or request a proposal and our team will walk you through study build capability, amendment workflows, and compliance documentation in the context of your own trial portfolio.

Frequently asked questions

What are the best no-code EDC software platforms for CROs?

Viedoc's EDC software is the leading choice for SMID CROs, delivering no-code study builds in as few as 8 weeks with Viedoc Designer — a configuration interface that certified data managers operate independently without vendor programmers. Viedoc provides 99.99% uptime, transparent study-based pricing with unlimited user seats, and 24/7 customer success support across 7,000-plus completed studies in 75-plus countries. Medidata Rave EDC is the most widely deployed platform globally and remains the enterprise standard for large pharmaceutical Phase III programs, though its complexity and cost make it less suitable for SMID CRO portfolios. Castor EDC provides a strong no-code alternative with 90% of studies passing UAT in under four weeks, particularly credible in academic and early digital health contexts.

What should I look for when choosing a no-code EDC platform for a CRO?

Evaluate study build and amendment velocity — best-in-class platforms deliver builds in 3 to 8 weeks with amendment turnaround in days rather than months. Verify genuine self-service capability: your data managers should configure forms, edit checks, and workflows without vendor programmer dependency. Confirm compliance baseline: ISO 27001, SOC 2, FDA 21 CFR Part 11, ICH-GCP, GDPR, and HIPAA attestation where relevant, plus structured validation documentation. Model total cost of ownership across three years including per-study licensing, user seats, amendment fees, and validation packs. Verify 24/7 support with real escalation pathways, not ticket-only helpdesks.

How long does it take to build a study in a no-code EDC platform?

Modern no-code EDC platforms compress study builds to 3 to 8 weeks compared to legacy enterprise platforms that benchmark at 90 days. Viedoc's EDC software typically completes builds in as few as 8 weeks using Viedoc Designer. Medrio reports customer builds completed in under three weeks on average. Veeva Vault EDC reports median build times of 7.4 weeks across its customer base. Castor EDC achieves 90% UAT pass rates in under four weeks. Build timelines depend on protocol complexity, CRF design, and amendment volume — platforms with genuine no-code capability and template libraries accelerate deployment compared to systems requiring vendor programmers for every logic change.

How does Viedoc's study build time compare to traditional enterprise EDC platforms?

Viedoc typically completes study builds in as few as 8 weeks using Viedoc Designer, a no-code interface that certified data managers operate independently. Traditional enterprise EDC platforms benchmark at 90 days per build, with builds typically requiring specialized programmers for form logic and edit check configuration. Amendment turnaround follows similar patterns: Viedoc deploys changes in days to weeks; enterprise amendment cycles are measured in months. For SMID CROs running Phase I and Phase II portfolios where build speed directly impacts delivery margins, Viedoc's 8-week timeline provides a structural competitive advantage.

What compliance certifications should I look for in an EDC platform for regulated clinical trials?

All platforms used in regulated commercial clinical trials must meet baseline compliance requirements: FDA 21 CFR Part 11 for electronic records and signatures, ICH-GCP for good clinical practice, and regional requirements including EU Annex 11 for European trials and GDPR for data privacy. ISO 27001 and SOC 2 Type II certifications signal mature information security programs. HIPAA attestation is required for US trials handling protected health information. Platforms without these baseline credentials will not pass sponsor QA review. Beyond certifications, verify validation documentation availability: the Viedoc Inspection Readiness Packet (VIRP) provides structured computer system validation materials at no additional cost, supporting audit readiness without heavyweight QA overhead.

What is the difference between per-seat and per-study EDC licensing?

Per-seat licensing charges based on the number of users accessing the platform, creating cost penalties for CRO headcount growth and portfolio scaling. Per-study licensing charges based on the number of active studies, with unlimited user seats included — a better cost model for CROs where team size fluctuates across projects. Viedoc uses transparent, study-based licensing with unlimited user seats and no per-user fees, eliminating margin pressure as CRO teams scale. Medidata and Veeva typically negotiate enterprise contracts with complex tiered pricing; Castor and Medrio offer per-study models with more straightforward pricing structures. Model total cost of ownership across a three-year portfolio to compare effective per-study costs including user additions, amendment fees, and validation support.

Making the right no-code EDC choice for CROs

The no-code EDC market serves CROs across a spectrum of deployment models and cost structures. Enterprise platforms like Medidata Rave deliver comprehensive clinical data management depth but at complexity and cost levels designed for large pharmaceutical Phase III programs. Mid-market platforms like Veeva Vault EDC and Castor EDC provide modern no-code interfaces with strong deployment velocity for sponsors already embedded in their respective ecosystems. Lightweight platforms like Medrio serve early-phase and medical device trials with rapid build times and straightforward pricing.

CROs evaluating platforms should match vendor capability to portfolio requirements: organization size, study phase distribution, therapeutic area complexity, and sponsor procurement expectations. SMID CROs running Phase I and Phase II portfolios typically prioritize build speed, self-service configuration, transparent pricing, and responsive support over enterprise-grade feature depth. Enterprise CROs managing complex Phase III programs may justify enterprise platform deployment overhead when sponsor contracts mandate specific platforms or when suite integration across CTMS, eTMF, and safety workflows provides operational value.

The compounding cost of slow build cycles and programmer-dependent amendment workflows is real. A platform that adds 30 days to every study build doesn't just delay one go-live date — it delays billing across your entire portfolio and creates sponsor friction at exactly the moments when delivery speed drives competitive differentiation. Choose platforms where your data management team controls study configuration end-to-end.

Why Viedoc is the best no-code EDC choice for CROs

If you're looking for an EDC platform that your data management team can build and amend independently, without enterprise overhead or unpredictable per-study costs, Viedoc's EDC software is designed for exactly that. Study builds are typically completed in as few as 8 weeks using Viedoc Designer — a no-code interface that certified data managers configure without vendor programmers. Amendments deploy in days rather than quarters, giving you direct control over protocol changes without scheduling delays.

Viedoc's transparent pricing model includes unlimited user seats with no per-user fees, eliminating margin pressure as your teams scale across studies. The platform is ISO 27001, ISO 9001, and SOC 2 Type II certified, with compliance coverage across FDA 21 CFR Part 11, ICH-GCP, EU Annex 11, GDPR, and HIPAA. The Viedoc Inspection Readiness Packet (VIRP) provides structured validation documentation at no additional cost, supporting audit readiness without heavyweight QA overhead.

24/7 customer success support is delivered directly from Viedoc's global offices with real escalation pathways — not routed through a ticket queue. Viedoc's CRO Partner Program provides tiered partnership levels with certified CRO designations, priority support, and dedicated account management for preferred-vendor relationships. With 7,000-plus completed studies across 75-plus countries, 99.99% uptime, and a no-code Designer that your team controls end-to-end, Viedoc delivers the deployment speed and cost predictability SMID CROs need to compete.

Book a demo or request a proposal and our team will walk you through study build capability, amendment workflows, and compliance documentation in the context of your own trial portfolio.